Organotypic Models in Drug Development
Herausgegeben:Schäfer-Korting, Monika; Stuchi Maria-Engler, Silvya; Landsiedel, Robert
Organotypic Models in Drug Development
Herausgegeben:Schäfer-Korting, Monika; Stuchi Maria-Engler, Silvya; Landsiedel, Robert
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This book provides latest findings in organotypic models in drug development and provides the scientific resonance needed in an emerging field of research in disciplines, such as molecular medicine, physiology, and pathophysiology. Today the research on human-based test systems has gained major interest and funding in the EU and the US has increased over the last years. Moreover, so-called 3R (reduce, replace, refine animal experiments) centres have been established worldwide.
Andere Kunden interessierten sich auch für
- Organotypic Models in Drug Development213,99 €
- Physiology, Pharmacology and Pathology of the Blood-Brain Barrier160,49 €
- Interaction of Nanomaterials with the Immune System110,99 €
- Safety and Efficacy of Gene-Based Therapeutics for Inherited Disorders110,99 €
- Manzoor M. KhanImmunopharmacology125,99 €
- Therapeutic Antibodies220,99 €
- Manufacturing of Gene Therapeutics166,99 €
-
-
-
This book provides latest findings in organotypic models in drug development and provides the scientific resonance needed in an emerging field of research in disciplines, such as molecular medicine, physiology, and pathophysiology. Today the research on human-based test systems has gained major interest and funding in the EU and the US has increased over the last years. Moreover, so-called 3R (reduce, replace, refine animal experiments) centres have been established worldwide.
Produktdetails
- Produktdetails
- Handbook of Experimental Pharmacology 265
- Verlag: Springer / Springer International Publishing / Springer, Berlin
- Artikelnr. des Verlages: 978-3-030-70062-1
- 1st ed. 2021
- Seitenzahl: 332
- Erscheinungstermin: 26. März 2021
- Englisch
- Abmessung: 241mm x 160mm x 23mm
- Gewicht: 725g
- ISBN-13: 9783030700621
- ISBN-10: 3030700623
- Artikelnr.: 60967184
- Handbook of Experimental Pharmacology 265
- Verlag: Springer / Springer International Publishing / Springer, Berlin
- Artikelnr. des Verlages: 978-3-030-70062-1
- 1st ed. 2021
- Seitenzahl: 332
- Erscheinungstermin: 26. März 2021
- Englisch
- Abmessung: 241mm x 160mm x 23mm
- Gewicht: 725g
- ISBN-13: 9783030700621
- ISBN-10: 3030700623
- Artikelnr.: 60967184
Inflammatory skin disease models in vitro and in animals - predictability for drug development.- Neural In Vitro Models for Studying Substances Acting on the Central Nervous System.- Quality of commercial tissues Standardised Reconstructed Skin Models in Toxicology and Pharmacology: State of the Art and Future Development.- Human-Derived In Vitro Models Used for Skin Toxicity Testing Under REACh.- Disease Models: Lung models for testing drugs against inflammation and infection.- In Vitro Models of the Blood-Brain Barrier.- How Qualification of 3D Disease Models Cuts the Gordian Knot in Preclinical Drug Development.- The CAM Assay as an Alternative In Vivo Model for Drug Testing.- Organotypic Models in Drug Development "Tumor Models and Cancer Systems Biology for the Investigation of Anticancer Drugs and Resistance Development.- Tissue Engineering for Musculoskeletal Regeneration and Disease Modeling.- Immunocompetent human intestinal models in preclinical drug development.- EngineeredHeart Muscle Models in Phenotypic Drug Screens.
Inflammatory skin disease models in vitro and in animals – predictability for drug development.- Neural In Vitro Models for Studying Substances Acting on the Central Nervous System.- Quality of commercial tissues Standardised Reconstructed Skin Models in Toxicology and Pharmacology: State of the Art and Future Development.- Human-Derived In Vitro Models Used for Skin Toxicity Testing Under REACh.- Disease Models: Lung models for testing drugs against inflammation and infection.- In Vitro Models of the Blood-Brain Barrier.- How Qualification of 3D Disease Models Cuts the Gordian Knot in Preclinical Drug Development.- The CAM Assay as an Alternative In Vivo Model for Drug Testing.- Organotypic Models in Drug Development “Tumor Models and Cancer Systems Biology for the Investigation of Anticancer Drugs and Resistance Development.- Tissue Engineering for Musculoskeletal Regeneration and Disease Modeling.- Immunocompetent human intestinal models in preclinical drug development.- EngineeredHeart Muscle Models in Phenotypic Drug Screens.
Inflammatory skin disease models in vitro and in animals - predictability for drug development.- Neural In Vitro Models for Studying Substances Acting on the Central Nervous System.- Quality of commercial tissues Standardised Reconstructed Skin Models in Toxicology and Pharmacology: State of the Art and Future Development.- Human-Derived In Vitro Models Used for Skin Toxicity Testing Under REACh.- Disease Models: Lung models for testing drugs against inflammation and infection.- In Vitro Models of the Blood-Brain Barrier.- How Qualification of 3D Disease Models Cuts the Gordian Knot in Preclinical Drug Development.- The CAM Assay as an Alternative In Vivo Model for Drug Testing.- Organotypic Models in Drug Development "Tumor Models and Cancer Systems Biology for the Investigation of Anticancer Drugs and Resistance Development.- Tissue Engineering for Musculoskeletal Regeneration and Disease Modeling.- Immunocompetent human intestinal models in preclinical drug development.- EngineeredHeart Muscle Models in Phenotypic Drug Screens.
Inflammatory skin disease models in vitro and in animals – predictability for drug development.- Neural In Vitro Models for Studying Substances Acting on the Central Nervous System.- Quality of commercial tissues Standardised Reconstructed Skin Models in Toxicology and Pharmacology: State of the Art and Future Development.- Human-Derived In Vitro Models Used for Skin Toxicity Testing Under REACh.- Disease Models: Lung models for testing drugs against inflammation and infection.- In Vitro Models of the Blood-Brain Barrier.- How Qualification of 3D Disease Models Cuts the Gordian Knot in Preclinical Drug Development.- The CAM Assay as an Alternative In Vivo Model for Drug Testing.- Organotypic Models in Drug Development “Tumor Models and Cancer Systems Biology for the Investigation of Anticancer Drugs and Resistance Development.- Tissue Engineering for Musculoskeletal Regeneration and Disease Modeling.- Immunocompetent human intestinal models in preclinical drug development.- EngineeredHeart Muscle Models in Phenotypic Drug Screens.